Clinical Trials Logo

ADHD clinical trials

View clinical trials related to ADHD.

Filter by:

NCT ID: NCT00824317 Completed - ADHD Clinical Trials

Stimulant Drug Treatment of Attention-Deficit Hyperactivity Disorder (AD/HD), Inattentive Type

Start date: October 2001
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the response to methylphenidate treatment of children with two different subtypes of ADHD.

NCT ID: NCT00784654 Completed - ADHD Clinical Trials

Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17

Start date: January 27, 2009
Phase: Phase 3
Study type: Interventional

The main aim of this study is to evaluate the long-term maintenance of efficacy of LDX after administered to children and adolescents aged 6-17 with ADHD for at least 6 months

NCT ID: NCT00782080 Completed - ADHD Clinical Trials

Efficacy and Safety of St. John´s Wort/Valerian Extract Versus Placebo in Children and Adolescents With ADHD

Start date: July 2008
Phase: Phase 3
Study type: Interventional

This study will determine the safety and efficacy of an herbal treatment in children and adolescents with ADHD. Study Design: - Randomized - Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) - Placebo Control - Parallel Assignment

NCT ID: NCT00764868 Completed - ADHD Clinical Trials

Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study

Start date: November 13, 2008
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the long-term safety of LDX administered as a daily morning dose (30, 50, and 70 mg/day) in the treatment of adolescents (13-17 years of age inclusive at the time of consent).

NCT ID: NCT00763971 Completed - ADHD Clinical Trials

Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17

Start date: November 17, 2008
Phase: Phase 3
Study type: Interventional

The main aim of this study is to see if giving LDX to children and adolescents aged 6-17 years with ADHD decreases symptoms of ADHD.

NCT ID: NCT00734578 Completed - ADHD Clinical Trials

Efficacy and Safety of SPD503 in Combination With Psychostimulants

Start date: September 2, 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of SPD503 in subjects with ADHD when co-administered with psychostimulants in children and adolescents aged 6-17 years with a diagnosis of ADHD with a sub-optimal, partial response to stimulants.

NCT ID: NCT00723684 Completed - ADHD Clinical Trials

Project Attention Deficit Hyperactivity Disorder (ADHD) and Electroencephalography (EEG)-Neurofeedback THERapy

PANther
Start date: July 2008
Phase: N/A
Study type: Interventional

Background: Electroencephalography (EEG)-neurofeedback has been shown to offer therapeutic benefits to patients with ADHD in several mostly uncontrolled studies with relatively small sample sizes. It is unknown how EEG-neurofeedback affects brain functioning and exerts therapeutic effects in ADHD. This study is designed to examine the efficacy and safety of EEG-neurofeedback in a scientific rigorously way and to study the underlying neurobiological mechanisms of EEG-neurofeedback. Objectives: 1. To investigate the efficacy of EEG-neurofeedback in reducing behavioral symptoms of ADHD. 2. To investigate whether EEG-neurofeedback is able to improve neurocognitive functioning. 3. To investigate whether EEG-neurofeedback is able to improve neural functioning. Study design: Double-blind randomized placebo-controlled treatment study.Study population: 120 subjects with ADHD (age 8-15, IQ of 80 or more). Intervention: 60 subjects with ADHD receive 30 sessions EEG-neurofeedback, and 60 subjects with ADHD receive placebo EEG-neurofeedback. Main study parameter: ADHD-DSM-IV rating scale, rated by the investigator. Hypothesis: The hypothesis is EEG-Neurofeedback can reduce symptoms of ADHD.

NCT ID: NCT00700323 Not yet recruiting - ADHD Clinical Trials

PS-Omega3 Supplementation to Attention Deficit Hyperactivity Disorder (ADHD) Children

ADHD-3
Start date: July 2008
Phase: Phase 2
Study type: Interventional

To assess the effect of phosphatidylserine-omega-3 consumption on the immune system parameters in children suffering from attention and concentration deficits.

NCT ID: NCT00697515 Completed - ADHD Clinical Trials

Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Start date: July 18, 2008
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of LDX compared to placebo in adults with ADHD in the adult workplace environment (AWE) setting

NCT ID: NCT00683462 Completed - ADHD Clinical Trials

An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)

Start date: May 2008
Phase: Phase 2
Study type: Interventional

A 3-way cross-over trial of two weeks of treatment with three drug conditions. AZD3480 will be given in doses of (A) 5mg/day, (B) 50 mg/day and (C) placebo to 24 non-smoking adults with DSM-IV confirmed ADHD. Three week washout between each treatment period. CYP2D6 genotyping will be completed at screening and slow metabolisers will be excluded from participation in this study. Cognitive, ADHD symptom, safety and pharmacokinetic (PK) assessments will be made during each treatment period. Safety and tolerability assessments will be a major component of the trial and all serious adverse events (SAE) will be immediately (within 24 hours) reported to both Targacept and to AstraZenca.